-transparent.png){kind=logo}
Antisera were raised against the retinal guanine-nucleotide-binding protein (N-protein), transducin, purified from bovine rod outer segments. Sera obtained after repeated injections of antigen recognized all transducin subunits (alpha, beta and gamma). One antiserum, tested for cross-reactivity with non-retinal N-proteins, was found to cross-react with the beta subunits of the ubiquitously occurring N-proteins, Ns and Ni, but not with their respective alpha and gamma subunits. The antiserum also cross-reacted with the beta subunit of the recently identified N-protein, No, which has been found in high abundance in the central nervous system. These data support the similarity of the beta subunits of the N-proteins identified so far. Purification of N-proteins from porcine cerebral cortex without the use of activating ligands yielded fractions containing the isolated alpha subunit of No, free beta gamma complex, Ni, No and fractions containing both N-proteins in various proportions. The purity of the preparations was at least 80% as judged by Coomassie-blue-stained SDS gels. No pure Ns was obtained. Use of the transducin antibody during the course of the purification revealed that the beta subunits coeluted from a gel filtration column largely with the alpha subunits of Ni and No but were hardly detectable in fractions that were able to reconstitute Ns activity into membranes of an Ns-deficient cell line (S49 cyc- lymphoma cells). This indicates that in the central nervous system the concentrations of Ni and No are of magnitudes higher than that of Ns. Two-dimensional gel electrophoresis of N-proteins, purified from porcine cerebral cortex, resulted in the resolution of two major peptides in the 35-kDa region, which differed in their pI values and were identified as beta subunits by the use of the antiserum. Identical results were achieved using crude cholate extracts from membranes of the same tissue instead of purified proteins. The occurrence of different beta subunits may be explained by posttranslational N-protein modification.
W Rosenthal, and
D Koesling, and
U Rudolph, and
C Kleuss, and
M Pallast, and
M Yajima, and
G Schultz
June 1990,
Molecular pharmacology,
W Rosenthal, and
D Koesling, and
U Rudolph, and
C Kleuss, and
M Pallast, and
M Yajima, and
G Schultz
March 1988,
Molecular pharmacology,
W Rosenthal, and
D Koesling, and
U Rudolph, and
C Kleuss, and
M Pallast, and
M Yajima, and
G Schultz
April 1994,
European journal of biochemistry,
W Rosenthal, and
D Koesling, and
U Rudolph, and
C Kleuss, and
M Pallast, and
M Yajima, and
G Schultz
June 1985,
Proceedings of the National Academy of Sciences of the United States of America,
W Rosenthal, and
D Koesling, and
U Rudolph, and
C Kleuss, and
M Pallast, and
M Yajima, and
G Schultz
March 1985,
FEBS letters,
W Rosenthal, and
D Koesling, and
U Rudolph, and
C Kleuss, and
M Pallast, and
M Yajima, and
G Schultz
February 1985,
Proceedings of the National Academy of Sciences of the United States of America,
W Rosenthal, and
D Koesling, and
U Rudolph, and
C Kleuss, and
M Pallast, and
M Yajima, and
G Schultz
November 1986,
Molecular pharmacology,
W Rosenthal, and
D Koesling, and
U Rudolph, and
C Kleuss, and
M Pallast, and
M Yajima, and
G Schultz
May 1986,
Molecular pharmacology,
W Rosenthal, and
D Koesling, and
U Rudolph, and
C Kleuss, and
M Pallast, and
M Yajima, and
G Schultz
December 1994,
Journal of pharmacological and toxicological methods,
W Rosenthal, and
D Koesling, and
U Rudolph, and
C Kleuss, and
M Pallast, and
M Yajima, and
G Schultz
January 1992,
Current topics in cellular regulation,
